Combined Epicardial and Endocardial Ablation for Treatment of Atrial Fibrillation. Ashkan Babaie MD Providence Portland Medical Center



Similar documents
DISCLOSURE. Atrial Fibrillation Management An Evidence-based Approach OBJECTIVES BACKGROUND AFFIRM 9/16/2015

Ablation For Atrial Fibrillation. Bill Petrellis Electrophysiologist


Atrial Fibrillation Catheter Ablation versus Surgical Ablation Treatment: FAST A Two-Center Randomized Clinical Trial

Surgeons Role in Atrial Fibrillation

Minimally Invasive Mitral Valve Surgery

How should we treat atrial fibrillation in heart failure

Atrial Fibrillation The Basics

DIU de rythmologie et stimulation cardiaque. Orateur : Serge BOVEDA Le 25 janvier 2012

CATHETER ABLATION for ATRIAL FIBRILLATION

COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION

Management of Symptomatic Atrial Fibrillation

Presenter Disclosure Information

The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It?

How do you decide on rate versus rhythm control?

Difficult Cases in Atrial Fibrillation. Ascot Cardiology GP Symposium April 2014

Adult Cardiac Surgery ICD9 to ICD10 Crosswalks

Thoracoabdominal aortic aneurysm

Management of Pacing Wires After Cardiac Surgery

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust

Treatments to Restore Normal Rhythm

Förmaksflimmer ablation - en uppdatering och guidelines. Carina Blomström Lundqvist, Dept.of Cardiology, Uppsala University Hospital.

Management of Atrial Fibrillation in Heart Failure

BIOSENSE WEBSTER NAVISTAR THERMOCOOL Catheter for Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation FDA review of P030031/S11

How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy

/$ -see front matter 2007 by the Heart Rhythm Society and the European Heart Rhythm Association,

Current ablation techniques for persistent atrial fibrillation: results of the European Heart Rhythm Association Survey

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

New in Atrial Fibrillation

Atrial Fibrillation (AF) Explained

Atrial Fibrillation: Drugs, Ablation, or Benign Neglect. Robert Kennedy, MD October 10, 2015

Atrial Fibrillation The High Risk Obese Patient

Atrial Fibrillation Know your risk of stroke Know your treatment options

CATHETER ABLATION FOR ATRIAL FIBRILLATION

PATIENT INFORMATION GUIDE TO ATRIAL FIBRILLATION

GUIDE TO ATRIAL FIBRILLATION

WATCHMAN Left Atrial Appendage Closure Device

Atrial Fibrillation An update on diagnosis and management

Advanced Treatment for Chronic Atrial Fibrillation

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

GUIDE TO ATRIAL FIBRILLATION

Catheter Ablation of Arrhythmogenic Foci as Treatment for Atrial Fibrillation

Introduction to Electrophysiology. Wm. W. Barrington, MD, FACC University of Pittsburgh Medical Center

Corporate Medical Policy

Patient Information Sheet Electrophysiological study

Atrial Fibrillation Management Across the Spectrum of Illness

ANTICOAGULATION IN ATRIAL FIBRILLATION. Heather Kertland St Michael s Hospital University of Toronto

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

The Maze Procedure- A Surgical Intervention for Ablation of Atrial. Fibrillation

Atrial Fibrillation Peter Santucci, MD Revised May, 2008

Managing the Patient with Atrial Fibrillation

Diagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses

The Difficult Mitral Valve Repair in Children, Leave with Stenosis or Regurgitation

How do you decide on rate versus rhythm control?

A Patient Guide to Atrial Fibrillation and Catheter Ablation

Atrial Fibrillation Management

Catheter Ablation. A Guided Approach for Treating Atrial Arrhythmias

ATRIAL FIBRILLATION. What you need to know

The debate: Should all AF patients see an EP consultant?

Name of Policy: Transcatheter Ablation of Arrhythmogenic Foci as a Treatment of Atrial Fibrillation

Atrial Fibrillation and Ablation Therapy: A Patient s Guide

Visited 9/14/2011. What is Atrial Fibrillation? What you need to know about Atrial Fibrillation. The Normal Heart Rhythm. 1 of 7 9/14/ :50 AM

Atrial Fibrillation New Treatment, New Hope. Atrial Fibrillation It Just Sucks. Atrial Fibrillation Disclosure Information 1/30/2014

Patient Information Leaflet about Pradaxa for Atrial Fibrillation. You Have Been Prescribed Pradaxa

Atrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center

National Medical Policy

Advances in the Treatment of Atrial Fibrillation At VCU Medical Center

Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

Current Management of Atrial Fibrillation DISCLOSURES. Heart Beat Anatomy. I have no financial conflicts to disclose

Listen to Your Heart. What Everyone Needs To Know About Atrial Fibrillation & Stroke. The S-ICD System. The protection you need

2014: nowadays the one shot technologies and the injectable monitor allow a wide and complete AF patient management. Why shouldn t we use them?

Resection of Lung Cancer Invading the Mediastinum

Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI

Atrial fibrillation. Treatment Guide

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

Transcatheter Mitral Valve-in-Valve and Valve-in-Ring Implantations. Danny Dvir, MD On behalf of VIVID registry investigators

ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014

Nursing Care and Considerations for Patients with Atrial Fibrillation. Kris Kinghorn RN, MSN, ANP-BC

Disclosures. Anesthesia and Lead Extractions. Lead Extractions: Objectives. Lead Removal Techniques. None

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

Reimbursement Information For Electrophysiology and Arrhythmia Service Procedures 1

Projected Number of Adults With AF in the US. Review the growing incidence and importance of AF in the population

ATRIAL FIBRILLATION: Scope of the Problem. October 2015

Tachyarrhythmias (fast heart rhythms)

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

RACE I Rapid Assessment by Cardiac Echo. Intensive Care Training Program Radboud University Medical Centre NIjmegen

Atrial Fibrillation: Do We Have A Cure? Raymond Kawasaki, MD AMG Electrophysiology February 21, 2015

The Heart and Vascular Institute at Englewood Hospital and Medical Center

Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular

Vorhofflimmern und Schlaganfall Ablation, Antikoagulation, Vorhofohrverschluß was wann für wen? B. Keweloh Unfallkrankenhaus Berlin

HTEC 91. Topic for Today: Atrial Rhythms. NSR with PAC. Nonconducted PAC. Nonconducted PAC. Premature Atrial Contractions (PACs)

What to Know About. Atrial Fibrillation

Cardioversion for. Atrial Fibrillation. Your Heart s Electrical System Cardioversion Living with Atrial Fibrillation

Atrial Fibrillation: The heart of the matter

Section: Surgery Last Reviewed Date: May Policy No: 177 Effective Date: July 1, 2015

Atrial fibrillation How is treatment changing? Charles Henrikson, MD Director, Electrophysiology Service 1 February 2014

Heart & Vascular Institute of New Jersey. Englewood Hospital and Medical Center

Transcription:

Combined Epicardial and Endocardial Ablation for Treatment of Atrial Fibrillation Ashkan Babaie MD Providence Portland Medical Center 1

Disclosures None 2

Cox-Maze III The Godfather Cure rates > 95% in patients with refractory AF All lesions were made by cut and sew incisions Required median sternotomy with cardiopulmonary bypass Includes left and right atrial appendage excision 3

Cox-Maze IV All lesions were made by alternative energy source rather than incisions Requires sternotomy or lateral thoracotomy with cardiopulmonary bypass 4

Multiple Ablation Sources are Avaialble Damiano et al. MMCTS:2007 5

Single Center Outcomes of Stand-Alone Cox-Maze over 20 years % Sinus Rhythm % Sinus Rhythm No antiarrhythmics Weimar et al. Circ Arrhythm Electrophysiol. 2012;5(1):8-14 6

Single Center Outcomes of Stand-Alone Cox-Maze over 20 years: Complications Cox-Maze III Cox-Maze IV 30 day mortality: 2 pts (2%) Median LOS: 9 days 10% complication rate Reoperation 3 pts (3%) IABP 4 pts (4%) Renal Failure 2 pts (2%) Early Stroke 1 pt (1%) 30 day mortality: 1 pt (1%) Median LOS: 7 days 1% complication rate Early Stroke 1 pt (1%) Weimar et al. Circ Arrhythm Electrophysiol. 2012;5(1):8-14 7

Minimally Invasive PV Isolation Is performed on beating heart via bilateral minithoracotomies or thoracoscopic ports Lesions are made on PV antra via clamp device Ganglionic Plexi can be ablated LOM dissection can be performed Left atrial appendage can be excised 8 McClelland et al. J Cardiovasc Electrophysiol. 2007;18:1289-95

Minimally InvasivePV isolation with GP Ablation Overall n=20 Paroxysmal n=11 Persistent n=5 Long-standing Persistent n=5 McClelland et al. J Cardiovasc Electrophysiol. 2007;18:1289-95 9

Minimally Invasive Atrial ablation with Linear Lesions for Treatment of Persistent Afib - Dallas Lesion Set Edgerton et al. Ann Thorac Surg 2009;88:1655 7 10

Minimally Invasive Atrial ablation with Linear Lesions for Treatment of Persistent Afib - Dallas Lesion Set Validation of linear lesions by pacing and looking for evidence of conduction delay Edgerton et al. Ann Thorac Surg 2009;88:1655 7 11

Limitations of Minimally Invasive Epicardial Ablation Isthmus-dependent atrial flutter is not treated Non-PV triggers cannot be evaluated or treated Is there a role for waiting time/adenosine/isoproterenol in looking for PV reconnection CS isolation/ablation cannot be performed Mitral Isthmus ablation is often unsuccessful Assessment of block in linear lesions can be difficult 12

Combined Procedures by Cardiothoracic Surgeon and Electrophysiologist Hybrid Ablation Convergent Ablation Minimally Invasive Atrial Ablation Pericardioscopic Atrial Ablation EPS Validation of PV isolation Validation/Completion of lines CAFE Right atrial lesions EPS Completion of PV isolation Validation of lines CAFE / Mitral Isthmus/ CS Right atrial lesions 13

Epicardial ablation device operates via unipolar RF Catheter is irrigated with suction also applied through lumen to improve tissue contact 14

QuickTime and a decompressor are needed to see this picture. 15

QuickTime and a decompressor are needed to see this picture. 16

EU Convergent Outcomes Baseline Information

EU Convergent Outcomes Summary of 12 and 24 month follow-ups % Sinus Rhythm % SR, off AADs Redos 18

EU Convergent Outcomes 6 to 24 Month Reveal XT Monitoring

4-Site Convergent Data Baseline Information AF Type (HRS Definitions) Number % Paroxysmal 19 16.5% Persistent & Longstanding 96 83.5% TOTAL 115 100% Demographics Average (SD) Age (years) 60.9 (8.0) AF Duration (years) 5.0 (5.3) Left Atrial Size (cm) 4.5 (0.7) LVEF (%) 54.4 (8.4) Body Mass Index (kg/m 2 ) 34.1 (7.4)

4-Site Convergent Data Epicardial Lesions Created Locations of Epicardial Lesions Epicardial Lesion % Created Posterior RPV 100% Posterior LPV 100% Superior Posterior Roof 97% Inferior Posterior Roof 64% Anterior RPV 98% Anterior LPV 100% Ligament of Marshall 28% PV to IVC 46% PV to CS 38% Right Atrial 0% slpv slpv ilpv LAA LAA 100% ilpv 38% 28% LV LV AORTA CS AORTA 97% 100% 100% 64% CS srpv 98% irpv 46% RAA SVC IVC RAA SVC srpv irpv IVC Epicardial Lesions Pericardial Reflections

4-Site Convergent Data Endocardial Lesions Created Endocardial Lesion % Created RSPV 90% RIPV 84% LSPV 93% LIPV 64% LA Roof 23% Posterior Wall 14% LAA 6% Septal Wall 12% RAA 3% SVC 7% Cavotricuspid Annulus 25% CS 7% slpv slpv 7% ilpv LAA ilpv Locations of Endocardial Lesions LAA 6% 93% 64% LV LV CS AORTA CS AORTA 23% 90% 14% 84% srpv irpv RAA SVC IVC RAA SVC srpv irpv 25% IVC 3% 7% Epicardial Lesions Pericardial Reflections Endocardial Lesions

4-Site Epicardial Data All Patients MACE ( 30 Days Post-Procedure) Major Adverse Cardiac Events( 30 Days) Incidence < 30 day Mortality 0% (0/115) Myocardial Infarction 0% (0/115) Stroke 0% (0/115) Transient Ischemic Attack 0.9% (1/115) Pulmonary Embolus 0% (0/115) Esophageal Fistula 0% (0/115) Phrenic Nerve Injury 0% (0/115) Pulmonary Vein Stenosis 0% (0/115) Tamponade 0% (0/115) Pericardial Effusion 1.7% (2/115) Bleeding Requiring Transfusion 1.7% (2/115) TOTAL 4.3% (5/115)

4-Site Epicardial Data All Patients Other Adverse Events ( 30 Days Post-Procedure) Other Adverse Events ( 30 Days) Incidence Acute Blood Loss from Drain 0.9% (1/115) Ileus 1.7% (2/115) Liver Hematoma 2.6% (3/115) Pseudoaneurysm 0% (0/115) TOTAL 5.2% (6/115)

4-Site Epicardial Data All Patients Outcomes Average F/U 11.4 months, n=115 % Sinus Rhythm % SR, +/- AADs % SR, off AADs % Redos 25

Avoiding Esophageal Injury During early development of the procedure atrioesophageal fistulas were observed in 4 patients at three different facilities.

Avoiding Esophageal Injury Risk Mitigation Steps Addressed Early Observations Risk Mitigation Steps Irrigate pericardial space during epicardial ablation to allow cooling Avoid endocardial ablation along posterior left atrium Esophageal temperature monitoring Change ablation technique for posterior wall to avoid inadvertent pericardial ablation Testing of Risk Mitigation Steps Performed Esophagoscopies on 30 consecutive patients No esophageal damage (erythema or ulceration) visually detected 2 days PO Thermal esophageal damage reported 4-56% with catheter ablation No Fistulas observed after risk mitigation steps during over 400 ablations

Providence Portland Experience 28

Providence Portland Experience Baseline Information All cases performed in EP lab Lab was retrofitted to allow thoracotomy and emergent CPB if needed Epicardial ablation performed by Dr. Douville After epicardial ablation drain is placed. Transeptal Access is the obtained - Goal ACT 300-350 PV isolation is completed and posterior line validated DC cardioversion Isoproterenol is administered at 20 mcg/min x 15 minutes looking for non- PV triggers Adenosine given looking for PV reconnection Cavotricuspid isthmus and SVC isolation performed Protamine given, sheaths removed in EP lab 29

Providence Portland Experience Baseline Information Short course of steroids for pericarditis Full anticoagulation next morning with lovenox/coumadin or pradaxa Antiarrhythmic for 6 weeks to 3 months Usual D/C hospital day 3 or 4 Close F/U over first 6 weeks, then at 3, 6 and 12 months 30

Providence Portland Experience Baseline Information - first 15 patients AF Type (HRS Definitions) Number % Paroxysmal 2 13.3% Persistent 7 46.7% Longstanding Persistent 6 40% TOTAL 15 100% Demographics Average (SD) Age (years) 60.6 AF Duration (years) 2.97 Left Atrial Size (cm) 4.7 (0.8) Left Atrial Size (ml/m 2 ) 44.7 (12.6)

Left Atrial Size of First 15 Ablation Patients Normal Mild Moderate Severe Left Atrial Size (ml/m 2 ) 32

Superior Pericardial Reflections Text Text Right Lower Pericardial Reflection Small Gap in Posterior Line 33

34

Progression of Epicardial Lesion Set 35

36

Providence Portland Experience First 15 patients Average F/U 11 months, n=15 % Sinus Rhythm % SR, off AADs % SR, off AADs % Redos After 1st Ablation 37

Providence Portland Experience First 15 patients % Sinus Rhythm % SR, off AADs % SR, off AADs % Redos After 1st Ablation 38

Providence Portland Experience Adverse Events (n=21) Adverse Events Adverse Events ( 30 Days) Incidence Intraoperative Arrest 1/15 Femoral Pseudoaneurysm 1/15 Adverse Events (> 30 Days) Incidence Incarcerated Hernia 1/15

Providence Portland Experience Lessons Learned There is a learning curve for the surgical procedure - probably around 10 cases All surgical lines need to be evaluated endocardially 2 recurrent tachycardias due to gaps in posterior line Empiric atrial flutter ablation added to lesion set 1 recurrent tachycardias due to atrial flutter There is a learning curve for the surgical procedure - probably around 10 cases Adenosine used to evaluate for latent conduction in PVs Avoid morbidly obese patients Approach cardiomyopathy patients with caution, especially when ablating near LAA 40